KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Invested Capital (2018 - 2025)

Historic Invested Capital for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $206.9 million.

  • Adaptive Biotechnologies' Invested Capital fell 755.63% to $206.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.9 million, marking a year-over-year decrease of 755.63%. This contributed to the annual value of $203.6 million for FY2024, which is 3399.01% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Invested Capital is $206.9 million, which was down 755.63% from $182.8 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Invested Capital registered a high of $725.7 million during Q1 2021, and its lowest value of $182.8 million during Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' median Invested Capital value was $396.0 million (recorded in 2023), while the average stood at $406.2 million.
  • In the last 5 years, Adaptive Biotechnologies' Invested Capital surged by 3157.46% in 2021 and then tumbled by 3899.47% in 2024.
  • Adaptive Biotechnologies' Invested Capital (Quarter) stood at $604.1 million in 2021, then fell by 23.16% to $464.2 million in 2022, then crashed by 33.56% to $308.4 million in 2023, then tumbled by 33.99% to $203.6 million in 2024, then rose by 1.62% to $206.9 million in 2025.
  • Its last three reported values are $206.9 million in Q3 2025, $182.8 million for Q2 2025, and $192.4 million during Q1 2025.